Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): November 6, 2007
GENESIS
PHARMACEUTICALS ENTERPRISES, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
Florida
|
333-86347
|
65-1130026
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
|
|
Middle
Section, Longmao Street, Area A, Laiyang Waixiangxing Industrial
Park
Laiyang
City, Yantai, Shandong Province, People’s Republic of
China
|
|
710075
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
(86)
535-7282997
(Registrant's
telephone number, including area code)
Copies
to:
Asher
S.
Levitsky, P.C.
Sichenzia
Ross Friedman Ference LLP
61
Broadway, 32nd
Floor
New
York,
New York 10006
Phone
(212) 981-6767
Fax
(212)
930-9725
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)
ITEM
1.01 ENTRY
INTO A MATERIAL DEFINITIVE AGREEMENT
ITEM
2.03 CREATION
OF A DIRECT FINANCIAL OBLIGATION
ITEM
3.02 UNREGISTERED
SALES OF EQUITY SECURITIES
On
November
6, 2007, Genesis Pharmaceuticals Enterprises, Inc. (the “Company”) entered into
a Securities Purchase Agreement with Pope Investments, LLC (the “Investor”)
pursuant to which the Company, on November 7, 2007 (the “Closing Date”) issued
and sold to the Investor, for $5,000,000 (a) 6% convertible subordinated
debentures due November 30, 2010 (the “Debenture”) and (b) a three-year warrant
(the “Warrant”) to purchase 10,000,000 shares of the Company’s common stock, par
value $0.001 per share, at an exercise price of $0.32 per share, subject to
adjustment as provided therein.
The
Debenture
bears interest at the rate of 6% per annum, payable in semi-annual installments
on May 31 and November 30 of each year, with the first interest payment being
due on May 31, 2008. The initial conversion price (“Conversion Price”) of the
Debentures is $0.25 per share. If the Company issues common stock at a price
that is less than the effective Conversion Price, or common stock equivalents
with an exercise or conversion price less than the then effective Conversion
Price, the Conversion Price of the Debenture and the exercise price of the
Warrant will be reduced to such price. The Debenture may not be prepaid without
the prior written consent of the Holder.
In
connection
with the Offering, the Company’s principal stockholder placed in escrow
20,000,000 shares of Common Stock, which shall be replaced by 20,000,000 shares
issued by the Company in the name of the escrow agent, at which time the shares
delivered by the principal stockholder will be returned. In the event the
Company’s consolidated Net Income Per Share (as defined in the Purchase
Agreement), for the year ended June 30, 2008 is less than $0.038, the escrow
agent shall deliver the 20,000,000 shares to the Investor.
Pursuant
to
the Securities Purchase Agreement, the Company entered into a Registration
Rights Agreement. Pursuant to the Registration Rights Agreement, the Company
must file on each Filing Date (as defined in the Registration Rights Agreement)
a registration statement to register the portion of the Registrable Securities
(as defined therein) as permitted by the Securities and Exchange Commission’s
guidance.
The
initial
registration statement must be filed within 90 days of the Closing Date and
declared effective within 180 days following the Closing Date. Any subsequent
registration statements that are required to be filed on the earliest practical
date on which the Company is permitted by the Securities and Exchange
Commission’s guidance to file such additional registration statement. Such
additional registration statements must be effective 90 days following the
date
on which it is required to be filed.
In
the event
that the registration statement is not timely filed or declared effective,
the
Company will be required to pay liquidated damages. Such liquidated damages
shall be, at the investor’s option, either $1,643.83 or 6,575 shares of Common
Stock per day that the registration statement is not timely filed or declared
effective as required pursuant to the Registration Rights Agreement, subject
to
an amount of liquidated damages not exceeding either $600,000, 2,400,000 shares
of Common Stock, or a combination thereof based upon 12% liquidated damages
in
the aggregate.
The
sale of
the Debenture and Warrants and the issuance of the 20,000,000 shares to be
held
in escrow are exempt from the registration requirements of the Act for the
private placement of these securities pursuant to Section 4(2) of the Act and/or
Rule 506 promulgated thereunder since, among other things, the transaction
did
not involve a public offering, the investors were accredited investors and
acquired the securities for investment and not resale, and the Company took
appropriate measures to restrict the transfer of the securities.
Copies
of the
Securities Purchase Agreement, Convertible Subordinated Debenture, Common Stock
Purchase Warrant, and the Registration Rights Agreement are filed as exhibits
to
this Current Report on Form 8-K. The summary of these agreements as set forth
above is qualified by reference to such exhibits.
(d)
Exhibits.
Exhibit
Number
|
|
Description
|
|
|
|
4.1
|
|
6%
Convertible Subordinated Debenture, dated November 7,
2007
|
4.2
|
|
Common
Stock Purchase Warrant, dated November 7, 2007
|
10.1
|
|
Securities
Purchase Agreement, dated as of November 6, 2007, between Genesis
Pharmaceuticals Enterprises, Inc. and Pope Investments,
LLC
|
10.2
|
|
Registration
Rights Agreement, dated as of November 6, 2007, between Genesis
Pharmaceuticals Enterprises, Inc. and Pope Investments,
LLC
|
10.3
|
|
Closing
Escrow Agreement, dated as of November 6, 2007, by and among Genesis
Pharmaceuticals Enterprises, Inc., Pope Investments, LLC and Sichenzia
Ross Friedman Ference LLP
|
99.1
|
|
Press
Release
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
GENESIS PHARMACEUTICALS ENTERPRISES,
INC. |
|
|
|
Dated: November
9, 2007 |
By: |
/s/ CAO
WUBO |
|
Cao
Wubo |
|
Chief
Executive Officer |